1.3.2. Transferring knowledge to clinical practice and scalable innovation actions

2013/743/EU: Council Decision of 3 December 2013 establishing the specific programme implementing Horizon 2020 - the Framework Programme for Research and Innovation (2014-2020) and repealing Decisions 2006/971/EC, 2006/972/EC, 2006/973/EC, 2006/974/EC and 2006/975/EC Text with EEA relevance · European Union

Clinical trials are an important means to transfer biomedical knowledge to application in patients, and support for these will be provided, as well as for the improvement of their practice. Examples include the development of better methodologies to allow trials to focus on relevant population groups, including those suffering from other concomitant diseases and/or already undergoing treatment; the determination of comparative effectiveness of interventions and solutions; and enhancing the use of databases and electronic health records as data sources for trials and knowledge transfer. Pre-clinical and/or clinical development of designated orphan drugs will be supported. Similarly, support for the transfer of other types of interventions, such as those related to independent living, into real world environments will be provided.

← anx_I__cpt_1__cpt_6__cpt_1__cpt_3__cpt_1__text_1 · All articles · anx_I__cpt_1__cpt_6__cpt_1__cpt_3__cpt_2__text_1 →

Source: EUR-Lex (Cellar) · retrieved 2026-11-04 · Text as adopted (Official Journal); later amendments are not incorporated in this text.